Medicago Planning Vaccine Production Facility in Durham, North Carolina
08/10/2010
"North Carolina's quality of work force, its training programs, and overall understanding of biotech development models were critical factors in our decision to locate in RTP," said Andy Sheldon, president and CEO of Medicago. "We are thrilled with our decision to build our vaccine facility in one of the largest and successful technology parks."
Medicago has received a $21 million research grant from the Defense Advanced Research Projects Agency (DARPA) to improve the production process of H1N1 vaccines. The company's project represents a total investment of more than $32 million in Research Triangle Park.
Most Read
-
-
Trends in Office and Industrial Parks
Q4 2020
-
The Future of the Workforce Is a “Better Normal”
Workforce Q4 2020
-
Another Look at Rural Economies
Q4 2020
-
Supply Chain Execs Respond as Pandemic Creates E-Commerce Surge
Q4 2020
-
Recruiting and Retaining Today’s Manufacturing Workforce
Workforce Q4 2020
-
Cold Storage Is Hotter Than Ever
Q4 2020